Search Results - peter+campochiaro

4 Results

Sort By:

Compositions and methods for controlled release suprachoroidal drug delivery

Unmet Need / Invention Novelty: Traditional routes of administrating drugs to the eye are limited by lack of efficiency, frequent side effects, and poor patient tolerance of repeated injections into the eye. Injections into the suprachoroidal space (SCS) is an attractive strategy to overcome these limitations and to provide for targeted delivery of...

Published: 3/14/2025 | Inventor(s): Laura Ensign-Hodges, Peter Campochiaro, Justin Hanes, Yoo Chun Kim, Jikui Shen, Jie Fu

Keywords(s): Disease Indication, Drug Delivery Mechanism, Drug Delivery Vehicle, Eye Disorders, Hydrogel, Local Ocular, Microspheres, Polymers, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities > Therapeutic Delivery Platforms

Nonviral Gene Transfer to the Suprachoroidal Space

Unmet Need:Gene transfer with adenoassociated viral (AAV) or lentiviral vectors can provide long-term expression in cells that have appropriate receptors for transduction. However, viral vectors induce an immune response making repeated administration impossible and also have limitations to cargo capacity. An alternative is nonviral gene transfer with...

Published: 3/13/2025 | Inventor(s): Peter Campochiaro, Jordan Green, Jikui Shen, Jayoung Kim

Keywords(s): Disease Indication, Dosed Therapeutic, Eye Disorders, Therapeutic Matter, Therapeutics

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities

Metipranolol for Treatment of Retinitis Pigmentosa

Unmet NeedRetinitis pigmentosa (RP) is a genetic disorder with a prevalence of 1 in 4000 people worldwide. RP can be the result of a number of mutations that all result in severe rod photoreceptor degeneration and death, causing excess oxygen in the outer retina and subsequent oxidative damage to cone photoreceptors. Symptom onset begins in childhood...

Published: 3/14/2025 | Inventor(s): Peter Campochiaro, Yogita Kanan, Ken Green

Keywords(s): Antagonists/Inhibitors, Disease Indication, Eye Disorders, Macular Degeneration, Non-novel, Predicted Novelty, Repurposed, Retinitis pigmentosa, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics

Category(s): Clinical and Disease Specializations > Ophthalmology > Retinitis Pigmentosa, Clinical and Disease Specializations > Ophthalmology > Macular Degeneration, Technology Classifications > Therapeutic Modalities > Small Molecules

Periocular Gene Transfer For Retinal and Choroidal Diseases

C03994: Therapeutic for Ocular-related DiseasesNovelty: A method of prophylactically or therapeutically treating an ocular disorder associated with abnormal neovascularization.Value Proposition: An overwhelming majority of the worlds population will experience some degree of vision loss in their lifetime, with the leading cause being ocular disorders....

Published: 3/13/2025 | Inventor(s): Peter Gehlbach, Peter Campochiaro

Keywords(s): Biologics, Disease Indication, Eye Disorders, Gene Therapy, Nucleic Acid, Peptide, Single, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Ophthalmology, Technology Classifications > Therapeutic Modalities > Biologics, Technology Classifications > Therapeutic Modalities > Gene Therapies, Technology Classifications > Therapeutic Modalities